R&D Scenario in Indian Pharmaceutical Companies
RESEARCH AND DEVELOPMENT SCENARIO IN INDIAN PHARMACEUTICAL COMPANIES
SUBMITED BY:
MR. SHAMSHAD AH
DEPARTMENT OF PHARMACEUTICAL MANAGEMENT
DEPARTMENT OF PHARMACEUTICAL MANAGEMENT
NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
SEC. NO. 67, S.A.S. NAGAR MOHLI PUNJAB
CONTENTS:
* OBJECTIVES....................................................................................3 * INTRODUCTION.............................................................................3 * STRENGTHS AND WEAKNESS OF INDIAN PHARMA COMPANIES……………………………………………………....4 * CHANGING TRENDS IN R & D………………………………....5 * WAYS OF FUNDING FOR R & D…………………………….....8 * RESEARCH OPTIONS FOR INDIA………………………..........9 * THERAPEUTIC AREAS OF NEW DRUG RESEARCH & DEVELOPMENT.............................................................................9 * ROLE OF PUBLIC SECTOR…………………………………....11 * FOREIGN INVESTMENT IN R&D.............................................13 * EMERGING R&D STRATEGIES IN PHARMACEUTICAL SECTOR..........................................................................................15 * THE KEY ELEMENTS OF CREATING ECOSYSTEMS…...…20 * CONCLUSION…………………………………………………...20 * REFERENCES…………………………………………………..20
1. OBJECTIVES One objectives of the post-1994 policy regime was the incentivisation of pharmaceutical research and development (R &D). Innovative products were given exemption from price control; a number of financial scheme were made available to firms for undertaking R&D; technology collaboration were brought under the automatic approval route; and most importantly, patent rights were granted for a period of 20 years for products as well as processes so what were the outcomes of these measures? Who are the major players? What are the therapeutics areas in which the R&D efforts are focused?
2. INTRODUCTION An important aspect of the
SUBMITED BY:
MR. SHAMSHAD AH
DEPARTMENT OF PHARMACEUTICAL MANAGEMENT
DEPARTMENT OF PHARMACEUTICAL MANAGEMENT
NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
SEC. NO. 67, S.A.S. NAGAR MOHLI PUNJAB
CONTENTS:
* OBJECTIVES....................................................................................3 * INTRODUCTION.............................................................................3 * STRENGTHS AND WEAKNESS OF INDIAN PHARMA COMPANIES……………………………………………………....4 * CHANGING TRENDS IN R & D………………………………....5 * WAYS OF FUNDING FOR R & D…………………………….....8 * RESEARCH OPTIONS FOR INDIA………………………..........9 * THERAPEUTIC AREAS OF NEW DRUG RESEARCH & DEVELOPMENT.............................................................................9 * ROLE OF PUBLIC SECTOR…………………………………....11 * FOREIGN INVESTMENT IN R&D.............................................13 * EMERGING R&D STRATEGIES IN PHARMACEUTICAL SECTOR..........................................................................................15 * THE KEY ELEMENTS OF CREATING ECOSYSTEMS…...…20 * CONCLUSION…………………………………………………...20 * REFERENCES…………………………………………………..20
1. OBJECTIVES One objectives of the post-1994 policy regime was the incentivisation of pharmaceutical research and development (R &D). Innovative products were given exemption from price control; a number of financial scheme were made available to firms for undertaking R&D; technology collaboration were brought under the automatic approval route; and most importantly, patent rights were granted for a period of 20 years for products as well as processes so what were the outcomes of these measures? Who are the major players? What are the therapeutics areas in which the R&D efforts are focused?
2. INTRODUCTION An important aspect of the
References: i. The Process of New Drug Discovery and Development, Second Edition, Charles G. Smith and James T. O 'Donnell, 2006, p. 422, published by Informa Healthcare. ii. "Food & Drug Administration, Generic Drugs: Questions and Answers". Food and Drug Administration, January 12, 2010. iii. Abhinav Agrawal, Kamal Dua, Vaibhav Garg, U.V.S. Sara and Akash Taneja, 27- Challenges and Opportunities for The Indian Pharma Industry, Health Administrator vol. xx number 1&2 : 109-113 iv. Kettler, white and jordin. v. KPMG 2005 AND Lintin and Nicholas 2007. vi. Abrol, et al 2011planning commission of India 2006. vii. Goddamn the Pusher Man, Reason, April 2010 viii. DSIR-IIFT and Prowess. THANK YOU SO MUCH